Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Better data for better insights and improved outcomes—Molecular Health has built one of the largest, deepest and fully curated digital platforms for biomedicine in the world. The company’s ‘Dataome’ provides the foundation for actionable insights for stakeholders across the healthcare ecosystem.
KaiPharm’s KMAP platform combines drug-induced transcriptome profiles and artificial intelligence to accelerate drug development and drug repositioning.
Combining cell sorting technology with artificial intelligence, Japan-based ThinkCyte aims to discover novel high-value therapeutic cells, new functional genes, and novel drug candidates for itself and its partners worldwide.
Deep Quartet, a drug discovery platform developed by INTAGE Healthcare and the Institute for Theoretical Medicine (ITM) uses AI technologies to design new lead compound structures based on pharmacophore models.
Our monthly roundup of 'business of science' stories from across Springer Nature’s portfolio of journals explores the relationships between academia, startups and big pharma, as well as following the progress of the COVID-19 vaccine rollout.
Vincerx applies a modular approach in the development of antibody–drug conjugates by incorporating novel targeting and safety features. The company’s lead compounds exhibit high efficacies with minimal toxicities that are expected to improve therapeutic windows. Vincerx believes that partners with first-in-class antibodies, clinical stage antibodies or ADCs against promising targets will benefit from Vincerx’s next-generation payload-linker technologies.
Gene therapy company FerGene Inc. is developing products for the treatment of urologic cancers, the company’s lead product, nadofaragene firadenovec, uses a non-replicating adenovirus vector to deliver the gene for interferon alfa-2b into bladder cells for the treatment of bladder cancer.
With its plug-and-play cell therapy platform and complementary bispecific NK cell engagers, Cytovia aims to create both single and combination therapies for cancer treatment.
Amarna Therapeutics has developed SVec, a non-immunogenic viral vector platform for the development of candidates to treat genetic and autoimmune disorders, overcoming immune barriers to gene therapy delivery and unlocking autoimmunity by inducing tolerance.
Sutro Biopharma combines its powerful cell-free protein synthesis platform with click chemistry to develop precisely engineered bioconjugate therapeutics for oncology.
A surge of efforts focused on the drug target B cell maturation antigen could transform the treatment of multiple myeloma and help to establish the relative merits and optimization strategies for emerging treatment modalities with wider applications.
Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative mechanism to existing cancer immunotherapy strategies. PT-112, Phosplatin’s lead ICD inducer, is in phase 2 clinical trials for metastatic castration-resistant prostate cancer, and could be applicable to other indications, including rare and refractory forms of cancer.
Cellestia Biotech AG is developing first-in-class therapies to control pathogenic gene expression by selective inhibition of previously undruggable transcription factors in the cell nucleus. The company’s clinical lead, CB-103, has advanced to phase 2 in oncology, followed by a rich R&D pipeline of novel gene transcription factor inhibitors targeting oncology, autoimmune and inflammatory disorders.
Biotech company Fibriant has developed a unique recombinant fibrinogen manufacturing platform that is able to create a range of products that offer advantages over the plasma version.
After a slow start due to the COVID-19 pandemic, oncology dealmaking thrived in 2020 as immuno-oncology fueled a number of high-value drug licensing deals and a string of billion-dollar M&As were announced.
Biotechnology company BioTheryX develops unique therapeutics for both oncology and inflammatory diseases based upon its novel protein degradation technology platform.
With its breakthrough dual-targeted natural killer cell therapy platform, ONK Therapeutics is creating its own pipeline of cell therapy candidates, and seeks to further unlock its potential through partnerships.
